A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus

Cancer Investigation

Volumn 24, Issue 3, 2006, Pages 229-234

  Kulke, Matthew H ^a   Wu, Bingyan ^a   Clark, Jeffrey W ^b   Enzinger, Peter C ^a   Lynch, Thomas J ^b   Vincitore, Michele ^a   Michelini, Ann ^a   Fuchs, Charles S ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

5 Fluorouracil; Chemotherapy; Cisplatin; Doxorubicin; Esophageal cancer; Gastric cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; ERYTHEMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646473367     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600633924     Document Type: Article

References (22)

1. Devesa, S.; Blot, W.; Frangioni, J.; Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83, 2049-2053.
2. Jemal, A.; Tiwari, R.; Murray, T.; et al. Cancer Statistics, 2004. CA Cancer J. Clinicians 2004, 54, 8-29.
3. Murad, A.; Santiago, F.; Petroianu, A.; Rocha, P.; Rodrigues, M.; et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72, 37-41.
4. Pyrhonen, S.; Kuitunen, T.; Nyandoto, P.; Kouri, M.; Randomised comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 1995, 71, 587-591.
5. Glimelius, B.; Ekstrom, K.; Hoffman, K.; et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997, 8, 163-168.
6. Wils, J.; Klein, H.; Wagener, D.; et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 1991, 9, 827-831.
7. Vanhoefer, U.; Rougier, P.; Wilke, H.; et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 2000, 18, 2648-2657.
8. Findlay, M.; Cunningham, D.; Norman, A.; et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 1994, 5, 609-616.
9. Webb, A.; Cunningham, D.; Scarffe, J.; et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advances esophagogastric cancer. J. Clin. Oncol. 1997, 15, 261-267.
10. Ross, P.; Nicolson, M.; Cunningham, D.; et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 2002, 20, 1996-2004.
11. Ajani, J.; Baker, J.; Pisters, P.; et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002, 94, 641-646.
12. Ilson, D.; Saltz, L.; Enzinger, P.; et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 1999, 17, 3270-3275.
13. Boku, N.; Ohtsu, A.; Shimada, Y.; et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 1999, 17, 319-323.
14. Moiseyenko, V.; Ajani, J.; Tjulandin, S.; et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc ASCO 2005, 23, A4002.
15. Brambilla, C.; Rossi, A.; Bonfante, V.; et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat. Rep. 1986, 70, 261-266.
16. The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 1988, 6, 679-688.
17. The Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J. Clin. Oncol. 1988, 6, 976-982.
18. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1959, 53, 457-481.
19. Ilson, D. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J. Clin. Oncol. 2002, 20, 1962-1964.
20. Levi, J.; Fox, R.; Tattersall, M.; Woods, R.; Thomson, D.; Gill, G. Analysis of prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J. Clin. Oncol. 1986, 4, 1348-1355.
21. Moertel, C.; Lavin, P. Phase II-III studies in advanced gastric cancer. Cancer Treat. Rep. 1979, 63, 1863-1869.
22. The Gastrointestinal Tumor Study Group. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat. Rep. 1979, 63, 1871-1876.